Lame for sure, but the most irksome data snooping may be changing the primary outcome to one of the 24 secondary outcomes very late in the study. LAME!!!
And then having the gov't sponsor this elaborate and enormous and expensive study of a drug with a mediocre track record for the BP, awash-in-cash, Gilead, while a cash-strapped startup with a more promising candidate treatment gets not a whit of help and is struggling mightily to get to full enrollment in a small, shoestring trial. Frustrating.
News 
Market Data 
Discover 
AI
